Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. Only a limited number of approved agents are available in the United States to treat DED. AbbVie’s blockbuster Restasis was the only FDA-approved therapy for 13 years, until the launch of Novartis’s Xiidra in 2016, the newer Restasis MultiDose formulation in 2017, Sun Ophthalmics’ Cequa in 2019, and Kala Pharmaceuticals’ Eysuvis and Oyster Point’s Tyrvaya in 2021. In addition to these drugs, off-label ophthalmic corticosteroids and antibiotics are often prescribed to manage DED. The claims analysis provides manufacturers of current treatments, as well as those developing novel agents, with real-world insight regarding recent trends in the use of drugs in DED.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DED patients?
- How have Restasis, Restasis MultiDose, Xiidra, Cequa, and Eysuvis been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of DED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DED patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Novartis, Sun Ophthalmics, Kala Pharmaceuticals
Key drugs: Restasis, Restasis MultiDose, Xiidra, Cequa, Eysuvis, other corticosteroids (ophthalmic), antibiotics (oral and ophthalmic)
Key analysis provided
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flowcharts
- Dry Eye - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Dry Eye Disease US February 2022
- Treatment Algorithms CDA Dry Eye Disease US 2022 Dashboard
Carolina Ruivo Pereira
Carolina Ruivo Pereira, Ph.D., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. Prior to joining the team, she worked as a content specialist in Cortellis, the suite of life science intelligence solutions from Clarivate. She holds a Ph.D. in biomedical sciences from Pompeu Fabra University in Barcelona, Spain, where she focused on identifying and characterizing novel genes implicated in lung carcinogenesis. She also holds a B.S. in biology from the University of Aveiro in Portugal.